Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Potential Targets and Mechanisms of Bitter Almond-Licorice for COVID-19 Treatment Based on Network Pharmacology and Molecular Docking

Author(s): Qiwei Hong, Xinyue Shang, Yanan Wu, Zhenlin Nie* and Bangshun He*

Volume 29, Issue 33, 2023

Published on: 23 November, 2023

Page: [2655 - 2667] Pages: 13

DOI: 10.2174/0113816128265009231102063840

open access plus

Abstract

Background: The outbreak of Corona Virus Disease 2019 (COVID-19) has resulted in millions of infections and raised global attention. Bitter almonds and licorice are both Traditional Chinese Medicines (TCM), often used in combination to treat lung diseases. Several prescriptions in the guidelines for the diagnosis and treatment of coronavirus disease 2019 (trial version ninth) contained bitter almond-licorice, which was effective in the treatment of COVID-19. However, the active ingredients, drug targets and therapeutic mechanisms of bitter almonds-licorice for the treatment of COVID-19 remain to be elucidated.

Methods: The active ingredients and targets were derived from the Traditional Chinese Medicine Systems Pharmacology (TCMSP). Meanwhile, targets associated with COVID-19 were obtained from the GeneCards database, PharmGkb database and DrugBank database. Then, the potential targets of bitter almond-licorice against COVID-19 were screened out. Protein-protein interaction (PPI) networks and core targets were analyzed through the String database and Cytoscape software. In addition, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed based on potential targets using R statistical software. Finally, molecular docking was used to validate the binding of the active ingredients to the core targets.

Results: The results of the TCMSP database showed that the bitter almond-licorice had 89 active components against COVID-19, involving 102 targets. PPI network and core target analysis indicated that IL-6, TNF, MAPK1, and IL1B were the key targets against COVID-19. In addition, GO and KEGG enrichment analysis showed that the bitter almond-licorice were involved in various biological processes through inflammation-related pathways such as TNF signaling pathway and IL-17 signaling pathway. Finally, molecular docking approaches confirmed the affinity between the active components of the bitter almond-licorice and the therapeutic targets.

Conclusion: The bitter almond-licorice could be used to treat COVID-19 by inhibiting inflammatory responses and regulating cellular stress. This work is based on data mining and molecular docking, and the findings need to be interpreted with caution.

Keywords: Bitter almond, licorice, COVID-19, network pharmacology, molecular docking, traditional chinese medicine.

« Previous Next »
[1]
Chams N, Chams S, Badran R, et al. COVID-19: A multidisciplinary review. Front Public Health 2020; 8: 383.
[http://dx.doi.org/10.3389/fpubh.2020.00383] [PMID: 32850602]
[2]
Sharma A, Ahmad FI, Lal SK. COVID-19: A review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses 2021; 13(2): 202.
[http://dx.doi.org/10.3390/v13020202] [PMID: 33572857]
[3]
Weekly Epidemiological Update on COVID-19 - 24 August 2022. 2022. Available from: https://www.who.int/publications/m/item/ weekly-epidemiological-update-on-COVID-19-24-august-2022
[4]
Medicine, Notice on Printing and Distributing the Guidelines for the Diagnosis and Treatment of Coronavirus Disease 2019 (trial version ninth). 2022. Available from: https://www.gov.cn/ zhengce/zhengceku/2022-03/15/content_5679257.htm
[5]
Guo C, Su Y, Wang H, et al. A novel saponin liposomes based on the couplet medicines of Platycodon grandiflorum–Glycyrrhiza uralensis for targeting lung cancer. Drug Deliv 2022; 29(1): 2743-50.
[http://dx.doi.org/10.1080/10717544.2022.2112997] [PMID: 35999702]
[6]
Chen K, Yin L, Li Z. Study on the prescription pattern of tradition Chinese medicine treatment for Corona virus disease 2019 in different province based on data mining. J Liaoning Univ 2021; 23(05): 100-7.
[7]
Yin L, Gao Y, Li Z, Wang M, Chen K. Analysis of chinese herbal formulae recommended for COVID-19 in different schemes in China: A data mining approach. Comb Chem High Throughput Screen 2021; 24(7): 957-67.
[http://dx.doi.org/10.2174/18755402MTEwqMzclw] [PMID: 33001008]
[8]
Yin X. Study on Literrature and Compatibility Rules of Armeniacae Semen Amarum. Anhui University of Chinese Medicine 2021; p. 69.
[9]
Guidelines for the diagnosis and treatment of coronavirus disease 2019 (trial version ninth) Chin J Viral Dise. 2019.
[10]
Chen X. Prediction of potential targets and mechanisms of GanCao-XingRen in the treatment of COVID-19 based on network pharmacology and molecular docking. J Hubei Univer 2021; 38(03): 15-21.
[11]
Dongxin W. The research of Licorice root decoct with Bitter almond, The seeds of commercial Semen NuX-vomica, Flos Datur differently and then compare the given components with decocting before. Henan University of Chinese Medicine 2007.
[12]
Zhou Z, Gao N, Wang Y, Chang P, Tong Y, Fu S. Clinical studies on the treatment of novel coronavirus pneumonia with traditional chinese medicine-a literature analysis. Front Pharmacol 2020; 11: 560448.
[http://dx.doi.org/10.3389/fphar.2020.560448] [PMID: 33013397]
[13]
Hu K, Guan W, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine 2021; 85: 153242.
[http://dx.doi.org/10.1016/j.phymed.2020.153242] [PMID: 33867046]
[14]
Zhang X, Gao R, Zhou Z, et al. A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19. Int J Med Sci 2021; 18(8): 1866-76.
[http://dx.doi.org/10.7150/ijms.53685] [PMID: 33746604]
[15]
Xu X, Bi J, Ping L, Li P, Li F. A network pharmacology approach to determine the synergetic mechanisms of herb couple for treating rheumatic arthritis. Drug Des Devel Ther 2018; 12: 967-79.
[http://dx.doi.org/10.2147/DDDT.S161904] [PMID: 29731604]
[16]
UniProt: A hub for protein information. Nucleic Acids Res 2015; 43(Database issue): D204-12.
[PMID: 25348405]
[17]
Safran M, Dalah I, Alexander J, et al. GeneCards version 3: The human gene integrator. Database 2010; 2010(0): baq020.
[http://dx.doi.org/10.1093/database/baq020] [PMID: 20689021]
[18]
Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92(4): 414-7.
[http://dx.doi.org/10.1038/clpt.2012.96] [PMID: 22992668]
[19]
Wishart DS. DrugBank and its relevance to pharmacogenomics. Pharmacogenomics 2008; 9(8): 1155-62.
[http://dx.doi.org/10.2217/14622416.9.8.1155] [PMID: 18681788]
[20]
Henry H, Gabriela VM, da Silva FR. InteractiVenn: A web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics 2015; 16(1): 015-0611.
[21]
von Mering C, Martijn H, Daniel J. STRING: A database of predicted functional associations between proteins. Nucleic Acids Res, 2003; 31(1): 258-61.
[22]
Gao K, YP Song and A. Song, Exploring active ingredients and function mechanisms of Ephedra-bitter almond for prevention and treatment of Corona virus disease 2019 (COVID-19) based on network pharmacology. BioData Min, 2020. 13(1): p. 19.
[http://dx.doi.org/10.1186/s13040-020-00229-4] [PMID: 33292385]
[23]
Wang Y, Xiao J, Suzek TO, et al. PubChem’s BioAssay database. Nucleic Acids Res 2012; 40(D1): D400-12.
[http://dx.doi.org/10.1093/nar/gkr1132] [PMID: 22140110]
[24]
Noguchi T, Akiyama Y. PDB-REPRDB: A database of representative protein chains from the Protein Data Bank (PDB) in 2003. Nucleic Acids Res 2003; 31(1): 492-3.
[http://dx.doi.org/10.1093/nar/gkg022] [PMID: 12520060]
[25]
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19(3): 141-54.
[http://dx.doi.org/10.1038/s41579-020-00459-7] [PMID: 33024307]
[26]
Ni L, Wen Z, Hu X, et al. Effects of Shuanghuanglian oral liquids on patients with COVID-19: A randomized, open-label, parallel- controlled, multicenter clinical trial. Front Med 2021; 15(5): 704-17.
[http://dx.doi.org/10.1007/s11684-021-0853-6] [PMID: 33909260]
[27]
Ren J, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020; 155: 104743.
[http://dx.doi.org/10.1016/j.phrs.2020.104743] [PMID: 32145402]
[28]
Xin S, Cheng X, Zhu B, et al. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment. Biomed Pharmacother 2020; 129: 110500.
[http://dx.doi.org/10.1016/j.biopha.2020.110500] [PMID: 32768975]
[29]
Chiow KH, Phoon MC, Putti T, Tan BKH, Chow VT. Evaluation of antiviral activities of Houttuynia cordata Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection. Asian Pac J Trop Med 2016; 9(1): 1-7.
[http://dx.doi.org/10.1016/j.apjtm.2015.12.002] [PMID: 26851778]
[30]
Yang X, Zhu X, Ji H, et al. Quercetin synergistically reactivates human immunodeficiency virus type 1 latency by activating nuclear factor-κB. Mol Med Rep 2018; 17(2): 2501-8.
[PMID: 29207194]
[31]
Mani JS, Johnson JB, Steel JC, et al. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res 2020; 284: 197989.
[http://dx.doi.org/10.1016/j.virusres.2020.197989] [PMID: 32360300]
[32]
Xu D, Hu MJ, Wang YQ, Cui YL. Antioxidant activities of quercetin and its complexes for medicinal application. Molecules 2019; 24(6): 1123.
[http://dx.doi.org/10.3390/molecules24061123] [PMID: 30901869]
[33]
Andres S, Pevny S, Ziegenhagen R, et al. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res 2018; 62(1): 1700447.
[http://dx.doi.org/10.1002/mnfr.201700447] [PMID: 29127724]
[34]
Guo H, Lin W, Zhang X, et al. Kaempferol induces hepatocellular carcinoma cell death via endoplasmic reticulum stress-CHOP-autophagy signaling pathway. Oncotarget 2017; 8(47): 82207-16.
[http://dx.doi.org/10.18632/oncotarget.19200] [PMID: 29137257]
[35]
Zhang W. Protectives effects of kaempferol against acetaminophen-induced acute liver injury in mouse. Guangdong Pharmaceutical University 2019.
[36]
Zhou YJ, Wang H, Li L, Sui HH, Huang JJ. Inhibitory effect of kaempferol on inflammatory response of lipopolysaccharide-stimulated human mast cells. Yao Xue Xue Bao 2015; 50(6): 702-7.
[PMID: 26521440]
[37]
Barve A, Chen C, Hebbar V, Desiderio J, Saw CLL, Kong AN. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm Drug Dispos 2009; 30(7): 356-65.
[http://dx.doi.org/10.1002/bdd.677] [PMID: 19722166]
[38]
Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005; 17(1): 86-95.
[http://dx.doi.org/10.1179/joc.2005.17.1.86] [PMID: 15828450]
[39]
Li Y. Naringenin attenuates myocardial injury by regulating AMPK/Nrf2/HO-1 signaling pathways in diabetic mice. Chin J Physiol 2020; 36(01): 38-46.
[40]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[41]
Tanaka T, Narazaki M, Masuda K, Kishimoto T. Regulation of IL-6 in immunity and diseases. Adv Exp Med Biol 2016; 941: 79-88.
[http://dx.doi.org/10.1007/978-94-024-0921-5_4] [PMID: 27734409]
[42]
Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016; 8(8): 959-70.
[http://dx.doi.org/10.2217/imt-2016-0020] [PMID: 27381687]
[43]
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol 2020; 20(6): 363-74.
[http://dx.doi.org/10.1038/s41577-020-0311-8] [PMID: 32346093]
[44]
Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect 2020; 9(1): 558-70.
[http://dx.doi.org/10.1080/22221751.2020.1736644] [PMID: 32172672]
[45]
Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect 2020; 50(4): 382-3.
[http://dx.doi.org/10.1016/j.medmal.2020.04.002] [PMID: 32259560]
[46]
Lai WY, Wang JW, Huang BT, Lin EPY, Yang PC. A novel TNF-α-targeting aptamer for TNF-α-mediated acute lung injury and acute liver failure. Theranostics 2019; 9(6): 1741-51.
[http://dx.doi.org/10.7150/thno.30972] [PMID: 31037135]
[47]
Behrens EM, Koretzky GA. Review: Cytokine storm syndrome: Looking toward the precision medicine era. Arthritis Rheumatol 2017; 69(6): 1135-43.
[http://dx.doi.org/10.1002/art.40071] [PMID: 28217930]
[48]
Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res 2015; 35(6): 600-4.
[http://dx.doi.org/10.3109/10799893.2015.1030412] [PMID: 26096166]

Rights & Permissions Print Cite
Article Metrics
35
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy